Irish Medical Times
October 5, 2016 by Gary Culliton
Access to hepatitis C treatment remains an important issue, Gary Culliton reports in his latest Clinical Update. There is currently a significant number of patients who are not eligible for direct-acting antivirals
There are two or three options for the treatment of genotypes one and four. Currently, one treatment is preferred for genotype 3 (sofosbuvir and daclatasvir are used — with or without ribavirin depending on whether the patient has cirrhosis). Newer agents held out the prospect of further options, said Dr Feeney.
Currently all treatments — depending on the genotype — are combinations of two or three antivirals
No comments:
Post a Comment